Key Takeaways
- In June 2026, SpaceX entered the public market with a valuation exceeding $2 trillion, securing its position among America’s elite companies
- Despite generating $18.67 billion in 2025 revenue, SpaceX reported a substantial $4.94 billion net loss
- Rocket Lab achieved unprecedented Q1 2026 revenue of $200.3 million, representing a 63.5% increase from the previous year
- Rocket Lab maintains a robust $2.2 billion backlog alongside more than $2 billion in available liquidity
- The two space companies present distinct investment opportunities: SpaceX brings massive scale while Rocket Lab offers accessible growth potential
For years, SpaceX has reigned supreme in the commercial space industry. When the company finally went public in June 2026, investors rushed to participate, driving its market capitalization beyond $2 trillion. This astronomical valuation places it firmly within the upper echelon of American corporations.
Meanwhile, Rocket Lab has been steadily constructing its own space enterprise. Though operating at a smaller magnitude, its rapid expansion has captured significant attention from investors seeking public market exposure to the space sector.
SpaceX: Enormous Revenue, Substantial Red Ink
SpaceX delivered $18.67 billion in revenue during 2025, marking a significant increase from the $14.02 billion recorded in 2024. However, aggressive investment in Starship development, Starlink infrastructure buildout, and various other initiatives resulted in a net loss of $4.94 billion.
Space Exploration Technologies Corp., SPCX
SpaceX’s business extends well beyond launching rockets. The company has created a unique dual-revenue model by pairing orbital launch services with Starlink’s satellite-based internet service—a combination unmatched by any publicly traded competitor.
Elon Musk has publicly projected that SpaceX could achieve $1 trillion in yearly revenue by 2030. Industry analysts remain considerably more skeptical about this ambitious forecast.
The optimistic investment thesis is straightforward: SpaceX dominates the launch industry and benefits from Starlink’s subscription-based revenue stream. The skeptical viewpoint is equally clear: shareholders are accepting premium valuations for a company still burning through billions annually.
Rocket Lab: Compact Scale, Impressive Momentum
Rocket Lab announced breakthrough first-quarter 2026 revenue of $200.3 million, reflecting 63.5% growth compared to the same period last year. The company’s full 2025 revenue totaled approximately $602 million. Its order backlog reached an all-time high of $2.2 billion, supported by total liquidity exceeding $2 billion.
Rocket Lab has evolved beyond its origins as a boutique launch provider. Today’s business encompasses launch operations, satellite manufacturing, defense contracts, and comprehensive space system solutions.
Yahoo Finance identified Rocket Lab as the most logical publicly traded benchmark for SpaceX as its IPO approached. Throughout SpaceX’s pre-listing period, numerous investors utilized Rocket Lab shares as a space sector proxy.
Rocket Lab’s investment appeal centers on operational delivery. The company’s Neutron rocket initiative, expanding contract pipeline, and diversifying space systems portfolio create multiple avenues for sustained expansion from its current foundation.
The cautious perspective acknowledges risks tied to contract scheduling, developmental milestones, and Neutron’s ultimate success. Rocket Lab remains far behind SpaceX in both revenue magnitude and launch frequency.
Contrasting Investment Philosophies
SpaceX represents industry dominance and transformative long-term potential. Rocket Lab presents a more transparent public-market growth narrative with valuation multiples that appear more achievable.
SpaceX likely possesses the superior underlying business model. Yet Rocket Lab may offer the more compelling equity story for investors prioritizing execution-driven upside within a manageable scale.
While both enterprises operate within the same sector, they target fundamentally different investor profiles.
